Abstract
Sequential subcutaneous PTH injection therapy (repeated 14 days of PTH administration and a subsequent treatment pause for a few weeks) is known to increase bone mineral density in patients with osteopenic disorders. Alternative methods of drug delivery may be beneficial in increasing compliance. A pilot study was performed in 10 healthy volunteers (4 female/6-male, age: 25.6 ± 3.5 years, BMI: 22.3 ± 2.4 kg/m2, mean ± SD) to assess the pharmacokinetic profiles of 1600 IU of PTH(1 - 34) using the pulmonary TechnosphereTM drug delivery system in comparison to a subcutaneous injection of 400 IU. The treatments were administered in the morning after an overnight fast and blood samples for measurement of PTH(1 - 34), PTH(1 - 84), and calcium and calcitonin were taken over a period of 6 hours. Both injection and pulmonary application of PTH(1 - 34) were well tolerated. After pulmonary administration of Technosphere/PTH(1 - 34), PTH(1 - 34) appeared in the serum with a faster concentration increase (Tmax: pulmonary 10 ± 5 min vs. subcutaneous 28 ± 8 min, p < 0.001) and with higher maximal concentrations (Cmax: pulmonary 309 ± 215 pmol/l vs. subcutaneous 102 ± 45 pmol/l, p < 0.05) as compared to the subcutaneous injection. The relative bioavailability of pulmonary Technosphere/PTH(1 - 34) was calculated to be 48 %. No differences were seen between pulmonary and subcutaneous application with regard to the PTH(1 - 84), calcitonin and calcium concentrations. In conclusion, pulmonary application of TechnosphereTM/PTH(1 - 34) appears to be an effective and thus attractive candidate for PTH substitution therapy in osteoporosis and other conditions leading to a decrease in bone mineral density.
Key words
Pulmonary Delivery - PTH(1 - 34) - Technosphere
References
-
1 Hodsman A B, Fraher L J, Watson P H. Parathyroid hormone: the clinical experiences and prospects. In: Whitfield JF, Morley P (eds) Anabolic treatments for osteoporosis. Boca Raton FL; CRC Press 1998: 83-108
-
2
Cosman F, Lindsay R.
Is parathyroid hormone a therapeutic agent of osteoporosis? A review of the clinical experience.
Calcif Tissue Int.
1998;
62
475-480
-
3
Hodsman A B, Watson P H, Drost D. et al .
Assessment of maintenance therapy with reduced doses of PTH(1 - 34) in combination with a raloxifene analogue (LY117018) following anabolic therapy in the ovariectomized rat.
Bone.
1999;
24
445-451
-
4
Lane N E, Sanchez S, Modin G W, Genant H K, Plerini E, Arnaud C D.
Parathytroid hormone treatment can reverse corticosteroid-induced osteoporosis.
J Clin Invest.
1998;
102
1627-1633
-
5
Neer R M, Aranud C D, Zanchetta J R, Prince R, Gaich G A, Reginster J Y, Hodsman A B, Eriksen E F, Ish-Shalom S, Genant H K, Wang O, Mitlak B H.
Effect of parathyroid hormone (1 - 34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
N Engl J Med.
2001;
344
1434-1441
-
6
Patton J S.
Pulmonary delivery of drugs for bone disorders.
Adv Drug Del Rev.
2000;
42
239-248
-
7
Lian H, Steiner S, Sofia R D, Woodhead J H, Wolf H H, White H S, Shen G S, Rhodes C A, McCabe R T.
A self-complementary, self-assembling microsphere system: Application of intravenous delivery of the antiepileptic and neuroprotectant compound felbamate.
J Pharm Sci.
2000;
89
867-875
-
8
Mohnike K, Bretschneider D, Brunelle P, Nihoul-Fekete C, Flacke F, Günther G, Pfützner A, Saudubray J M, Steiner S.
Continuous s. c. infusion with glucagon and intermittent s. c. treatment with octreotide in persistent hyperinsulinaemic hypoglycemia of infancy (PHHI).
Exp Clin Endocrinol Diabetes.
2000;
108 (Suppl. 1)
S127
-
9
Pfützner A, Heise T, Steiner S, Heinemann L, Rave K.
Inhaled Technosphere/Insulin shows a low variability in metabolic action in Type 2 diabetes.
Diabetes.
2000;
49 (Suppl. 1)
A121
-
10
Pohl R, Muggenburg B A, Wilson B R, Woods R J, Burell B E, Steiner S S.
A dog model as predictor of the temporal properties of pulmonary Technosphere/Insulin in humans.
Resp Drug Delivery.
2000;
VII
463-465
-
11
Rave K, Heise T, Pfutzner A, Steiner S, Heinemann L.
Results of a dose-response study with a new pulmonary insulin formulation and inhaler.
Diabetes.
2000;
49 (Suppl. 1)
A75
-
12
Steiner S, Pfützner A, Rave K, Heise T, Harzer O, Flacke F, Heinemann L.
Bioavailability and pharmacokinetic properties of inhaled dry powder Technosphere/Insulin.
Exp Clin Endocrinol Diabetes.
2002;
110
17-21
-
13
Lindsay R, Nieves J, Hennerman E, Shen V, Cosman F.
Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1 - 34): kinetics and biochemical responses in estrogenized osteoporotic patients.
J Clin Endocrinol Metab.
1993;
77
1535-1539
-
14
Rucinski B, Mann G N, Epstein S.
A new rapid and reproducible homologous immunoradiometric assay for amino-terminal parathyroid hormone in the rat.
Calcif Tissue Int.
1995;
56
83-87
-
15
Patton J S.
Breathing life into protein drugs.
Nat Biotech.
1998;
16
141-143
-
16
Patton J S, Platz R M.
Pulmonary delivery of peptides and proteins for systemic action.
Adv Drug Deliv Rev.
1992;
8
179-196
-
17
Kohler D.
Aerosolized insulin.
J Aerosol Med.
1994;
7
307-314
-
18
Fraher L J, Avram R, Watson P H, Hendy G N, Henderson J E, Chong K L, Goltzman D, Morley P, Willick G E, Whitfield J F, Hodsman A B.
Comparison of the biochemical responses to human parathyroid hormone-(1 - 31)NH2 and hPTH-(1 - 34) in healthy humans.
J Clin Endocrinol Metab.
1999;
84
2739-2743
-
19
Kanzawa M, Sugimoto T, Kobayashi A, Chiara K.
Association between parathyroid hormone (PTH)/PTH-related peptide receptor gene polymorphism and the extend of bone mass reduction in primary hyperparathyroidism.
Horm Metab Res.
2000;
32
355-358
-
20
Hodsman A B, Steer B M, Fraher L J, Drost D J.
An evaluation of several biochemical markers for bone formation and bone resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
J Clin Invest.
1991;
91
1138-1148
-
21
Howie D C, Bowsher R R, Brunelle R L, Woodworth J R.
[Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin.
Diabetes.
1994;
43
396-402
-
22
Hodsman A B, Fraher L J, Watson P H, Ostbye T, Stitt L W, Adachi J D, Taves D H, Drost D.
A randomized controlled clinical trial to compare the efficiency of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
J Clin Enodcrinol Metab.
1997;
82
620-628
Andreas Pfützner, M. D., Ph. D.
IKFE GmbH
Parcusstraße 8 · 55116 Mainz · Germany ·
Telefon: + 49 (6131) 5763660
Fax: + 49 (6131) 5763666
eMail: AndreasP@IKFE.de